Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
Date:5/8/2012

clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.  A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain, and AcelRx plans to initiate a Phase 2 study funded by a grant from USAMRMC, contingent on approval of the proposed clinical protocol for the study by USAMRMC.

Forward Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals' financial viability, anticipated increases in research and development and general and administrative expenses, the sufficiency of funds to support its clinical trials and operations, planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including the anticipated timing for clinical trials, progress towards initiation of the remaining Phase 3 study for ARX-01 and the Phase 2 study for ARX-04, and the therapeutic and commercial potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials; the uncertain clinical development process, including the risk that planned clinical trials may not begin on time, have an effective design, enroll a sufficient number of patients, or be initiated or completed on schedule, if at all; any delays or inability to obtain, regulatory approval of its
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Massachusetts y LONDRES, August 30, 2015 /PRNewswire/ ... ofrece una visión holística de l ... todo el trayecto   ... hoy el debut europeo de IntelliSpace Cardiovascular , ... que ofrece sofisticadas herramientas para acceder, analizar y compartir ...
(Date:8/28/2015)... According to a new market ... Prostate) Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... 17,689.0 Million USD by 2020 at a CAGR of ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... 28, 2015  Today, in final recognition of the ... Health Week, 1-800 Contacts is sharing how to keep ... lens wearers who do not properly care for their ... infections. Most contact lens wearers understand ... clean lens case is sometimes overlooked.  When proper steps ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 51-800 Contacts Shares Tips on How to Clean Lens Cases 2
... a global biopharmaceutical leader in the research and development ... and central nervous system conditions, is proud to support ... arthritis (RA) and epilepsy through three unique scholarship programs. ... more than 400 scholarships—totaling more than $3 million—to individuals ...
... Cardiac Science Corporation (Nasdaq: ... external defibrillator ( AED ) and diagnostic cardiac ... Microvolt T-Wave Alternans (MTWA) module that integrates with ... . (Logo:   http://photos.prnewswire.com/prnh/20080306/AQTH510LOGO ) ...
Cached Medicine Technology:UCB Awards More Than 100 Scholarships in 2010, Transforming the Lives of People with Severe Diseases 2UCB Awards More Than 100 Scholarships in 2010, Transforming the Lives of People with Severe Diseases 3UCB Awards More Than 100 Scholarships in 2010, Transforming the Lives of People with Severe Diseases 4Cardiac Science Introduces MTWA Module for Stress Testing 2Cardiac Science Introduces MTWA Module for Stress Testing 3Cardiac Science Introduces MTWA Module for Stress Testing 4Cardiac Science Introduces MTWA Module for Stress Testing 5
(Date:8/31/2015)... ... ... MeYou Health ®, a social well-being company and wholly owned subsidiary ... including an in-app step tracker. , Walkadoo is a pedometer-based walking program ... broadly assign every Walkadoo member 10,000 steps a day (as is typical for many ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s big news for ZendyHealth ... healthcare industry. , Consumer driven health plans (CDHPs) are a growing phenomenon, and ... strategic role to the company, and another to answer customers’ questions directly. , John ...
(Date:8/31/2015)... ... 31, 2015 , ... The Brooks Group, a global sales ... department devoted to helping organizations identify and keep the best talent both inside ... Brooks Group believes in offering a solution that goes beyond simply providing assessments ...
(Date:8/31/2015)... ... August 31, 2015 , ... Now here’s some good health news: Nearly two-thirds ... half your grains whole,” with the majority of Americans eating more whole grains than ... (WGC) released these findings and others from the 2015 Whole Grains Consumer Insights ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... ACTION. NOT CHANCES. (SM) will be featured on a digital screen projected above ... is designed to inspire and promote earlier awareness of the symptoms of ovarian ...
Breaking Medicine News(10 mins):Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:Most Americans Now Make Half Their Grains Whole 2Health News:Most Americans Now Make Half Their Grains Whole 3Health News:Most Americans Now Make Half Their Grains Whole 4Health News:Most Americans Now Make Half Their Grains Whole 5Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3
... study suggests that middle-aged smokers with heavily wrinkled faces ... than their un-wrinkled peers//. The study explains that having ... as chronic obstructive pulmonary disease (COPD). ,A ... Hospital on 149 people conducted the study, and it ...
... New Zealanders who take party pills in higher doses as ... pills escape people from taking drugs. ,Nearly 20% ... once – says researchers commissioned by the Ministry of Health. ... such as sleeplessness, loss of appetite, strange thoughts and irritability, ...
... Indian pharma industry is well positioned to capture much of ... next year, a new KPMG study reveals//. ,"The Indian ... global industry worth $650 billion - and is growing at ... percent," said John Morris, global head of KPMG's pharmaceuticals practice, ...
... diabetes, one of the world’s leading debilitating diseases, has reached ... adults worldwide. Therefore, there is a huge demand for innovative ... ,There are two types of diabetes: ... 5% of all the cases. This type is the direct ...
... team to investigate the outbreak of anthrax that has left ... in the past few weeks //. ,The KNP ... decide on the course of action based on the evidence ... South Africa biggest tourist attraction, which is roughly the size ...
... completely avoid consuming Vitamin E supplements, as this is fraught ... ,A leading obstetrician, Prof Stuart Campbell, has appealed to the ... clinical trials that have revealed that this vitamin can cause ... to increase the rates of still births and cause the ...
Cached Medicine News:Health News:Study States Smokers With Wrinkled Faces More Easily Prone To COPD 2Health News:KPMG Optimistic About Indian Pharma’s Growt 2Health News:Inhaled Insulin: A New Modality for Management of Diabetes 2Health News:S.Africa Sets Up Task Team To Investigate Anthrax Outbreak In KNP 2
... Tri-Active is the result of ... the combination of three different methods ... to your skin. This treatment is ... of cellulite through the combined action ...
... is a CO2 laser system with ... Its functions in continuous and super-pulsed ... extreme laser intervention delicacy. Excellent as ... it comes with a large LCD ...
... Kowa VK-2 is a professional digital imaging ... the features you need to acquire, analyze, ... because the tools you use the most ... superior results quickly and easily. This high-resolution ...
Pain management can be complicated. But that doesn't mean your PCA infusion system should be. The new SYNDEO PCA Syringe Pump streamlines pain therapy with a powerful combination of intelligent desig...
Medicine Products: